Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07220343 · ClinicalTrials.gov registry record · NA

Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer

A NA study of Cancer and Adolescents, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT07220343: Recruiting NA study of Cancer and Adolescents, sponsored by Stanford University.

NCT07220343 is a NA study of Cancer and Adolescents that is actively recruiting participants, run by Stanford University. The registered enrollment target is 25 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07220343, a NA study of Cancer and Adolescents, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.

Primary Outcome

The Beck Depression Inventory-II (BDI-II; range 0-63) will be used to measure changes in depressive symptoms among adolescents and young adults over time. Higher scores indicate greater depressive symptom severity.

Conditions Studied

Interventions

  • DEVICE Device
  • BEHAVIORAL Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App

Study Locations (1)

California

  • Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2025-01-29
Est. Completion 2026-12
Phase NA
Stanford University

1,744 total trials

What NCT07220343 shows while recruiting

NCT07220343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Device is the first listed.

NCT07220343 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07220343 about?

NCT07220343 is a clinical study titled "Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer". The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.

What is the current status of trial NCT07220343?

This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2025-01-29. Estimated completion is 2026-12.

What conditions does trial NCT07220343 study?

This clinical trial studies the following conditions: Cancer, Adolescents.

What interventions are being tested in trial NCT07220343?

The interventions under investigation include: Device (DEVICE), Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App (BEHAVIORAL).

Who is sponsoring clinical trial NCT07220343?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07220343 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07220343's enrollment target sits among peer trials

25 537th of 615 higher than 71 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07220343, the US trial registry maintained by the National Library of Medicine. NCT07220343 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.